A closely watched clinical trial in Britain that screened blood for early detection of cancer did not show a reduction in diagnoses at later stages of the disease. By Rebecca Robbins and Gina Kolata A ...

"No cancer signal detected." The blood test results popped up in my online health portal without much fanfare. A doctor would chat about them with me later, congratulating me on the "phew"-worthy ...

A simple, though not necessarily easy, test may help predict how many years a person has left, according to exercise researchers who have been tracking thousands of middle-aged and older people for ...

For many, the beep test is seared into memory. And not just the test itself, but the wave of dread that came before hearing that first beep in school physical education (PE) classes. Also known as the ...

Add Futurism (opens in a new tab) Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. One of the industry’s ...

Patients should receive training on the proper use of the delivery device prior to starting treatment. The Food and Drug Administration (FDA) has approved Onapgo™ (apomorphine hydrochloride [HCl]) for ...

A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients. Serina Therapeutics, based ...

(RTTNews) - Supernus Pharmaceuticals, Inc. (SUPN), a biopharmaceutical company, announced on Tuesday the FDA approval of ONAPGO or apomorphine hydrochloride for the treatment of motor fluctuations in ...

Feb 4 (Reuters) - The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' (SUPN.O), opens new tab drug-device combination to treat movement-related symptoms of Parkinson's disease ...

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced Parkinson's disease, Supernus Pharmaceuticals announced on Tuesday. The ...

Onapgo, a subcutaneous apomorphine infusion device, is approved for advanced Parkinson's disease, offering continuous symptom management without surgery. The TOLEDO trial showed apomorphine infusion ...